|First name||Last name:||Email:||Institution:||Group:||Telephone number:||Research field (check all that apply)||Short description of your research:|
|Carl Johan||Sundbergemail@example.com||Physiology & Pharmacology||Molecular Exercise Physiology||46705176886||Preclinical/Clinical||Regular physical activity provides health benefits for men and women of all ages, ranging from reduced risks of cardiovascular diseases, diabetes and certain types of cancer, to enhanced skeletal muscle capacity. These benefits can all be ascribed to the adaptations that gradually occur with repeated exercise.
Physical training affects a multitude of tissues throughout the human body. For instance, maximal cardiac output increases, the amount of body fat decreases, glucose control is improved and blood pressure is reduced. Our research mainly focuses on the exercise-induced mechanisms that take place in skeletal muscle and adipose tissue in healthy individuals, elite athletes and in patients with breast cancer.
|Olle||Kämpefirstname.lastname@example.org||Medicine (Solna)||Experimental Endocrinology||0708-151400||Preclinical/Clinical||Our research group uses rare and homogenous disorders as models in order to better understand autoimmunity at the B and T cell level, e.g. Addison's disease with complex inheritance and monogenic disorders such as APS-1 with mutations in the AIRE gene with defects in central tolerance and IPEX with mutations in the FOXP3 gene lacking T regulatory cells. We have made the original identification of autoantibodies against e.g. 21-hydroxylase in Addison’s disease, side-chain cleavage in autoimmune premature ovarian insufficiency and NALP5 in autoimmune hypoparathyroidism, today all used in clinical routine world wide.|
|Anna-Karin||Welmeremail@example.com||KI, NVS, Aging Research Center||Medical group||+46 8-6906866||Clinical||Anna-Karin’s primary area of research interest is the epidemiology of physical function, disability and falls in older persons. Currently she is working with the following research lines:
1.Exploring the complex interactions between biological, demographic, and social factors; chronic diseases; and lifestyle that may explain the development of disability in old age.
2.The European MPI (Multidimensional Prognostic Indices) project, which aims to use the MPI to predict survival in older individuals.
3.The body-mind connection.
4.The VR-financed project: “Thinking, moving, and falling: Early detection of fall-prone phenotypes as targets for primary interventions—a translational study”. The goal of this project is to enable early detection of fall risk in older adults who can be targets for primary interventions.
|Gerald||Coorayfirstname.lastname@example.org||Clinical Neuroscience||Neuro Hyllienmark||Clinical||Mathematical modelling of cortical activity in epilepsy. Our main interest is in increasing the understanding of the physiology of the epileptic brain. We study the pathophysiological activity during epileptic seizure activity with intention of modelling and understanding seizure initiation and spread. Moreover, we are also investigating the effect of chronic electrical stimulation over epileptic regions of the brain with intent on understanding the physiological changes that occur which have shown to reduce seizure activity. We use neurophysiological recordings in patients with epilepsy using both non-invasive and invasive EEG and non-invasive MEG.|
|Karin||Brobergemail@example.com||Institutet för miljömedicin||Metaller och hälsa||737823750||Preclinical/Clinical||Vi undersöker hur metaller i miljön, tex i dricksvatten och föda, påverkar risk för sjukdom. Vi har ett särskilt fokus på exponering tidigt i livet och hur det påverkar barnets utveckling. Vi studerar olika mekanismer för metalltoxicitet: hormonella, epigenetiska, genetiska och metabola.|
|Kajsa||Müllersdorffirstname.lastname@example.org||LIME||-||-||Clinical||Using a knowledge based decision support to collect and analyze patient medical history. Goal is to improve management of care and clinical outcome. Ongoing study at Danderyds Sjukhus in collection of data from patients presenting with chest pain at the emergency.|
|Anna||Krook||Anna.Krook@ki.se||Physiology & Pharmacology||Integrative physiology||-||Preclinical||Det övergripande syftet med forskningen inom integrativ fysiologi är att upptäcka och definiera riktpunkter som är viktiga inom metabola sjukdomar, till exempel vid nedsatt glukos homeostas och typ 2-diabetes mellitus.
Forskargruppen fokuserar på att identifiera de underliggande mekanismer som styr olika metabola sjukdomar. I synnerhet, men inte enbart med fokus på, insulinresistens i skelettmuskulatur.
Vi har utvecklat en unik metod för att studera human muskel, och var först med att identifiera vilka molekylära steg som är nedreglerade i insulinsignaleringskedjan i muskel från personer med typ 2-diabetes mellitus. Många försök utförs också på odlad human muskel, både från friska personer och från personer med diabetes för att kartlägga sjukdomsbilden på molekylär nivå.
Ett annat viktigt område för gruppens forskning är effekten av fysisk aktivitet/muskel kontraktion. Fysisk aktivitet ökar muskelns insulinkänslighet, och kan förbättra glukosmetabolismen hos personer med diabetes.
Please see http://ki.se/en/fyfa/integrative-physiology
|Annika||Scheyniusemail@example.com||Department of Clinical Science and Education, Karolinska Institutet, and Sachs' Children and Youth Hospital, Södersjukhuset||own||070-6057927||Preclinical/Clinical||Mechanisms behind allergy
Allergic diseases are one of the commonest causes of chronic ill health causing personal suffering and increasing socio-economic and health care costs. There is a great need for novel initiatives within health care for prevention, specific diagnosis and treatment. My overall aim to increase understanding of the mechanisms behind allergy is: 1) to characterize the role of environment and lifestyle, including in utero environment, with a focus on host-microbe, epigenetic and gene-environment interactions in the development of allergy, and 2) to elucidate mechanisms by which allergens interact with our immune system, to provide knowledge on how the body´s own regulatory mechanisms can be used for prevention and treatment. The project is performed in a cross-disciplinary international network with front-line competence spanning from clinical and epidemiological research, immunology, microbiology, molecular and cell biology, metagenomics and epigenetics. This project will result in better understanding how to disentangle risk from protective factors in the development of allergic diseases leading to novel strategies for prevention and treatment and create diagnostic tools to discover new subgroups of patients.
|Gert||Helgessonfirstname.lastname@example.org||LIME||Stockholm Centre for Healthcare Ethics||-||Preclinical/Clinical||We are doing research in medical ethics, which includes empirical and theoretical (philosophical) work. The main applied fields are healthcare ethics and medical research ethics.|
|Jan-Bernd||Stukenborgemail@example.com||KBH||Pediatric Endocrinology Unit; Nordfertil Research Lab Stockholm||852482788||Preclinical||Fertility preservation techniques for children suffering gonadotoxic treatments (e.g. studies on ex vivo cultures of gonadal tissue; in vitro differentiation of pluripotent stem cells; studies on gonadal development)|
|Per||Uhlénfirstname.lastname@example.org||Department of Medical Biochemistry and Biophysics (MBB)||Uhlén Lab||070-6642814||Preclinical||Our research group is studying developmental and cancer related processes in various types of cells. The biological platforms that we are applying are tissue slices, primary cell cultures, cell lines and stem cells. To study the processes of cell division, cell differentiation, and neural migration/networking we are applying state-of-the-art imaging techniques and modern genetic tools, such as single-cell sequencing and transgenic animals. Our focus is to shed light on the intracellular cell signaling mechanisms that regulate these vital processes for development and disease.|
|Yihai||Caoemail@example.com||MTC||Yihai Cao||+468 5248 7596||Preclinical||Preclinical angiogenesis research in obesity and cancer|
|Tie-Qiang||Lifirstname.lastname@example.org||CLINTEC||Functional imaging||707374215||Preclinical/Clinical||Neuroimaging of the human brain|
|Per||Söderstenemail@example.com||NVS||applied neuroendocrinology||704133022||Preclinical/Clinical||Recovery from under- and overweight by machine - the mind is in the jaw - chewing for brain development - virtual eating|
|Amaia||Calderón-Larrañagafirstname.lastname@example.org||Karolinska Institutet (Department of Neurobiology, Care Sciences and Society, NVS)||Aging Research Center||+34647433637||Clinical||My research focuses on the study of environmental and behavioural determinants of health changes in the older population using data from the Swedish National Study on Aging and Care (SNAC).|
|Tina||Dalianis||Tina.Dalianis@ki.se||Department of Oncology-Pathology||TinaDalianis/AndersNäsman/Cinzia Bersani||707910297||Preclinical/Clinical||Studies of human papillomavirus and other tumor viruses in cancer|
|Ganesh||Acharyaemail@example.com||CLINTEC||Head of the Division of Obstetrics and Gynecology, CLINTEC||+46 858587523||Preclinical/Clinical||Placental Biology, Pregnancy complications, Fetal Medicine|
|Agneta||Nordbergfirstname.lastname@example.org||NVS||Translational Alzheimer Neurobiology||070 5107685||Preclinical/Clinical||Translational reasearch in alzheimer´s disease and other related dementia disorders with the aim to develop and use PET imaging tracers to be studiesi autopsy large bran sectios (autoradography) as well as in living patients from presymtomatic stage and whole diease progression.|
|Lalit Kumar||Parameswaran Grace||Lalit.email@example.com||Women's and Children's health||Kristina Gemzell Danielsson||704757457||Preclinical||1. Stem cells in endometrial regeneration. 2. Endometriosis and endometriosis associated cancer. 3. Endometrial receptivity and human embryo implantation|
|Richard||Rosenquist Brandellfirstname.lastname@example.org||Dept of Molecular Medicine and Surgery||Clinical Genetics||070-6253384||Preclinical/Clinical||Cancer genomics|
|Anthony||Wrightemail@example.com||LABMED||Kliniskt forskningscentrum, gene regulation group||070 641 48 92||Preklinisk||lymfomutveckling och utveckling av resistens mot läkemedel|
|Jesper||Lagergrenfirstname.lastname@example.org||Molekylärmedicin och kirurgi||Upper Gastrointestinal Surgery||851776012||Preclinical/Clinical||The research examines diseases and surgical procedures of the oesophagus and stomach, with a focus on causes, prevention and treatment of oesophageal cancer and conditions associated with this tumour, i.e. Barrett's oesophagus, gastro-oesophageal reflux and obesity.|
|Weimin||Yeemail@example.com||MEB||Weimin Ye||52486184||Preclinical/Clinical||We work on etiology, early detection, and prognosis of head & neck cancer and upper gastrointestinal tract cancers.|
|Debora||Rizzutofirstname.lastname@example.org||Department of Neurobiology, Care Sciences and Society||Aging Research||-||Preclinical||My research activity focuses on investigating the most relevant factors that lead to longer and healthier life. Using a life-course perspective I am exploring the role of health status, lifestyle factors, social environment, and genetic background on late-life health and survival.|
|Christopher||Hübelemail@example.com||Medicinsk epidemiologi och biostatistik||CEDI - Centre for Eating Disorders Innovation||-||Preclinical/Clinical||At the Centre for Eating Disorders Innovation (CEDI) we are dedicated to applying novel and emerging methodologies and technologies to elucidate causal mechanisms underlying eating disorders. Our ultimate goal is to rigorously apply findings from genetic, biological, and environmental risk investigations to refine and personalize detection, prevention, and treatment of eating disorders.|
|Nele||Brusselaersfirstname.lastname@example.org||Microbiology, Tumour and Cell biology||Centre for Translational Microbiome Research||-||Clinical||Clinical epidemiology|
|Ewa||Ehrenborgemail@example.com||Department of Medicine, Solna||Per Eriksson||070-788 6191||Preclinical/Clinical||ROLE OF AUTOPHAGY IN ATHEROSCLEROSIS
Recently, a link between lipid droplet (LD) associated proteins, reverse cholesterol transport and autophagy has been shown in mice, suggesting an important role in the pathogenesis of atherosclerosis. Autophagy is a highly conserved self-protecting process as cellular response to stress, in which cellular components are self-consumed and recycled for downstream metabolism. Misfolded proteins and organelles e.g. mitochondria and LDs are selective substrates of macroautophagy whereas specific LD associated proteins are substrates for chaperone-mediated autophagy (CMA). The most abundant LD protein for metabolically active cells is perilipin 2 (PLIN2) and its degradation by CMA seems to be dependent on different drugs.
To explore the function of PLIN2 in humans, we employ a genetic strategy where we study functional genetic variants with different approaches ranging from detailed cell and molecular biology to genetic epidemiological analyses of cardiovascular disease.
We are also characterizing the role of autophagy markers in relation to atherogenesis and plaque vulnerability for putative therapeutic purposes. Analyses in progress of central autophagy proteins show that they are mainly expressed in vulnerable regions of human carotid plaques. Interestingly, plaque autophagy appears to be influenced both by metabolic status and drug treatment. In these studies we also investigate human tissues originating from different biobanks as well as atherogenic mice models.
|Anton||Lagerfirstname.lastname@example.org||Department of Public Health Sciences||PRIME Health||722471988||Preclinical/Clinical||Public health epidemiology with focus on major diseases and determinants. Head of Unit, Health Situation and Care Needs Analysis, Centre for Epidemiology and Community Medicine (CES, SLL). Topics include: GBD, geographical health differences, epidemiological surveillance, incident diabetes type 2, mental health among children and youth, eating disorders, obesity, physical activity, labour market position among young people, IQ and emotional skills, education's effect on IQ/emotional control/dementia/mortality, equal access to health care, and the association between parental income and life expectancy.|
|Monika||Ehnmanemail@example.com||Onkologi-Patologi||Arne Östman||739997382||Preklinisk/Klinisk||Translational research studies on soft-tissue sarcoma with a focus on how tumor cells interact with infiltrating stroma cells in a context-dependent manner. Ongoing projects deal with immune cell infiltration and how stroma cells are molecularly reprogrammed in the tumor microenvironment during tumor progression. We are particularly interested in the platelet-derived growth factor family of growth factors as sarcoma drivers and drug targets.|
|Elias||Arnér||Elias.Arner@ki.se||MBB||Division of Biochemistry, Arnér group||08-52486983||Preclinical||We work on selenoproteins and redox control of cell function, with a special focus on molecular mechanisms and applications in cancer therapy.|
|Lars||Rydénfirstname.lastname@example.org||Medicin K2||Lars Rydéns grupp för Diabetesforkning/Prevention||707292171||Clinical||Vi bedriver kliniskt inriktad forskning som syftar till att minska risken för hjärt-kärlsjukdom i samband med diabetes ffa av typ 2. Kliniska prövningar, stora som små, Europabaserade undersökningar om vårdkvalitet ochmetider för screening för att spåra individer med prediabetes eller tidigare okänd diabetes ingår. Gruppen är produktiv och internationellt mycket väl förankrad med många nationella och internationella samarbetspartners.|
|Agneta||Richter-Dahlfors||Agneta.Richter.Dahlfors@ki.se||Neuroscience||Swedish Medical Nanoscience Center||08 52487425||Preclinical||At the Swedish Medical Nanoscience Center we promote efficient integration of cutting edge technologies and medical research. We aim to solve biological and medical problems, focussing particularly on bacterial infection, using various kinds of nano-technological approaches.|
|Keira||Melicanemail@example.com||Neuroscience||Swedish Medical Nanoscience Center||08 52487069||Preclinical||In my group we are studying 'Tissue Microbiology'. We have projects available focussing on Staphylococcus bacteria in a humanised model of skin infection/colonisation. We use a number of techniques including intravital microscopy.|
|Pär||Nordlundfirstname.lastname@example.org||Oncology and Pathology||Pär Nordlund||Preclinical||The group has developed a novel strategy for discovering clinical biochemical biomarkers that bear the potential to improve drug therapies for different cancers. The technology, Cellular Thermal Shift Assay (CETSA), allows for the direct quantification of biochemical changes of activation states of proteins in patient samples.|
|Mattias||Güntheremail@example.com||Neurovetenskap||Risling||701729266||Preclinical/Clinical||Experimentell traumatologi, fysiologistudier på gris, men även cellkulturer|
|Ning||Xu Landénfirstname.lastname@example.org||Department of Medicine Solna, Karolinska Institutet||N Xu Landén's group||762345626||Preclinical||Both chronic non-healing wounds and psoriasis are major and rising health and economic burdens worldwide and lack of effective treatment. Investigation of the role of regulatory RNAs, for example microRNA and long non-coding RNAs, represents an emerging concept, and constitutes a promising area for pharmaceutical intervention. The goal of our laboratory is to unravel the role(s) of regulatory RNAs in skin wound healing and in psoriasis. Moreover, we aim to translate basic scientific findings into therapeutic interventions for patients.|
|Petter||Brodin||Petter.email@example.com||Medicine, Solna||Petter Brodin||852481396||Preclinical/Clinical||Systems Immunology, newborn immune system development, computational biology|
|Peder||Olofssonfirstname.lastname@example.org||Department of Medicine, Solna||Olofsson||851771667||Preclinical/Clinical||Neural control of vascular inflammation|
|Elin||Rönnberg Höckerlindemail@example.com||Medicin, Enh. för immunologi och allergi||Gunnar Nilsson||076-8117819||Preclinical||Mast cells are strongly implicated in the pathogenesis of asthma. However, the role of different mast cell populations and mediators in the pathology of asthma remain unclear. In this study, we hypothesize that there is a phenotypical and functional heterogeneity among human lung mast cells that play a pivotal role for the features of asthma and we aim to characterize the heterogeneity in unbiased ways. We will perform single cell RNA sequencing on human lung mast cells, and we have used a flow cytometry panel of 334 different markers and have found novel and interesting markers with a high degree of expression variability within the mast cell population. Co-staining of identified markers, from the 2 different approaches, will be analyzed to define novel mast cell subpopulations that will be isolated and investigated for their differences in functionality. We have identified expression of several frizzled receptors. The agonists to the Frizzled receptors are Wnts and Wnt signaling is primarily involved in embryonic development, proliferation, differentiation and tissue damage/repair. Recent findings have implicated Wnt pathways in critically regulating inflammatory responses, especially in asthma. The role(s) of Wnt signaling in mast cells is however unknown and to further investigate this we will first the in vitro response of mast cells too different Wnts and look at receptor activation, proliferation, differentiation, reactivity and cytokine production of the mast cells.
|Liv||Eidsmofirstname.lastname@example.org||MedS||Eidsmo||768125004||Preclinical/Clinical||Jag är hudläkare och immunolog. Genom studier av hudens T celler försöker min grupp hitta mer effektiva behandlingar av hudsjukdomar som vitiligo och psoriasis. Målet är att öka kunskap om immunsystemet i frisk och sjuk vävnad. Det är oändligt spännande att få vara del av en forskningsrörelse som förändrar synen på grundläggande immunologi genom att flytta fokus från blod och in vitro försök till humana vävnader. Man kan också söka på våra senaste studier och pressnytt från ki.se i våras för att lära mer om vårt arbete.|
|Eduardo||Villablancaemail@example.com||MedS, Karolinska Institutet||Mucosal Immunology group (Villablanca)||08 517 759 34||Preclinical||We try to understand the mechanism underlying immune-mediated intestinal disorders|
|Anna||Fogdell-Hahn||Anna.Fogdell-Hahn||Klinisk Neurovetenskap||Klinisk Neuroimmunologi||08-51770251||Preclinical/Clinical||Immunogenicitet hos läkemedel, tester för anti-läkemedelsantikroppar, multipel skleros, humant herpesvirus 6, http://www.cmm.ki.se/group/klinisk-immunologi-fogdell-hahn-2/|
|Ingrid||Kockumfirstname.lastname@example.org||Department of clinical neuroscience||Genetic epidemiology of multiple sclerosis||767808001||Preclinical/Clinical||Our research group studies genetic epidemiology of multiple sclerosis (MS), including different measures of outcome of disease including biomarkers for disease. We are studying interaction between lifestyle exposures affecting risk of MS and genetic risk factors. We are also studying the genetic control of immune response to viruses that affect the risk of developing MS and potential autoantigens for MS.|
|Cecilia||Boldemannemail@example.com||PHS K9 Dept of Public HEalth Sciences||0737 44 57 68||Preclinical||Synergetic mpact of outdoor physical environment upon children's health|
|Lars||Jakobssonfirstname.lastname@example.org||Medical Biochemistry and Biophysics||Jakobsson||703186244||Preclinical/Clinical||Our aim is to find new ways of manipulating the blood or the lymphatic vascular system to treat diseases such cancer, stroke, diabetes complications and genetic vascular malformation . We use genetically modified mice in which we can delete genes in a subpopulation of cells that also can be identified by fluorescent reporters. We apply advance microscopy (live of static), in living mice and whole fixed organs. We apply a flurry of technologies including single-cell sequencing. Please see http://ki.se/en/mbb/lars-jakobsson-group for more info|
|Annelie||Falkevallemail@example.com||MBB-division of vascular biology||Ulf eriksson||736821739||Preclinical||Role of VEGF-B and lipotoxicity in diabetes and diabetic complications|
|Roman||Zubarevfirstname.lastname@example.org||MBB||Kemi I||87594||Preclinical||proteomics; mass spectrometry; chemical proteomics; drug target identification; ageing; Alzheimer's disease; cancer cell death; origin of life; isotopic resonance|
|Jens||Hjerling Leffleremail@example.com||MBB||Hjerling-Leffler Group||08-52486974||Preclinical||Molecular Neuroscience, single-cell sequencing, electrophysiology, mouse genetics. Please visit www.hjerling-leffler-lab.org for more information|
|Ana||Teixeirafirstname.lastname@example.org||MBB||Ana Teixeira Group||Preclinical||Nanomedicine (teixeiralab.com)|
|Maria||Sabater Llealemail@example.com||Karolinska Institutet||Cardiovascular Medicine||851773221||Preclinical||It is now every time more common to use the so called “organ-on-a-chip” structures to study in vitro the function and behaviour of different diseases and cell-mechanisms in a set-up that is more close to the physiological conditions that the more traditional in vitro cell work. The organ-on-a-chip are microchips that recapitulate the microarchitecture and functions of living organs, such as the lung, heart, and intestine.
The aim of the project is to establish a microchannel system that can mimic a vessel, and that can be used to assess the effect of particular candidate genes, flow conditions, or blood components on the endothelial cell, specially referring to platelet adhesion and thrombus formation.
|Katja||Petzoldfirstname.lastname@example.org||MBB||Petzold||-||Preclinical||We work with structural biology/Biophysics of RNA and try to understand how RNA moves in order to perform its biological function|
|Nicola||Crosettoemail@example.com||MBB||https://bienkocrosettolabs.org||-||Preclinical||We are interested in understanding how the 3D architecture of the genome shapes the higher propensity of DNA to break in certain regions. In particular, we are interested in understanding how chromatin dynamics throughout the cell cycle and the interplay between DNA replication and transcription are linked to the formation of DNA double-strand breaks (DSBs) along the genome. We have pioneered the first method, BLESS, for mapping the genomic location of DSBs (Crosetto et al, Nat Meth 2013), and recently we have developed a powerful improvement, BLISS, which allows quantitative genome-wide analysis of DSBs even in low-input samples (Yan et al, Nat Commun 2017). We combine DSB detection methods with state-of-the-art chromosome conformation capture assays (HiC), high-resolution DNA and RNA in situ fluorescence hybridization methods (Bienko, Crosetto et al, Nat Meth 2013), and methods newly developed in our lab that interrogate the radial positioning of chromosomes in the cell nucleus.|
|Paul||Gerdhemfirstname.lastname@example.org||CLINTEC||Enheten för ortopedi och bioteknologi||0736-994409||Klinisk||Kliniska studier; observationsstudier och randomiserade kontrollerade studier inom ryggsjukdomar. Biokemiska och genetiska studier på kliniska material inom ryggsjukdomar, speciellt skolios|
|Gabriel||Sandblomemail@example.com||KI SöS||Surgery||704158218||Clinical||Reseach mainly focused on management of biliary pancreatitis, gallstone disease and abdominal wall surgery. Clinical research based on patient registers, retrospective patient record reviews and randomised controlled trials.|
|Konstantinos||Ampatzisfirstname.lastname@example.org||Karolinska Institutet||Ampatzis||700520325||Preclinical||We are working on neuroplasticity mechanisms that allow the neuronal networks to be flexible and adaptable in light to new environmental demands. In our lab we focus on the vertebrate spinal networks controlling locomotion and on cerebellum involvement on motor and non-motor (cognitive, memory) functions.|
|Eva||Hedlundemail@example.com||Neuroscience||Hedlund lab||08-52487884||Preclinical||We try to elucidate mechanisms of neuronal vulnerability and resistance in neurodegenerative disease, with a particular focus on amyotrophic lateral sclerosis|
|Arne||Holmgrenfirstname.lastname@example.org||MBB||Biokemi/Arne Holmgren||070-6467686||Preclinical||Redox biologi|
|Dasiel Oscar||Borroto Escuelaemail@example.com||Department of Neuroscience. KI||Fuxe lab||760396319||Preclinical||We are primarily focused on understanding the molecular integration of signals in the brain via receptor-receptor interaction in the heteroreceptor complexes and its functional effects . We are also interested in whether alterations in specific heteroreceptor complexes and their receptor-receptor interactions are associated with and/or play a role in pathogenetic mechanisms contributing to brain disease development, inter alia Parkinson's disease, schizophrenia, addiction and depression. We are very excited by the tremendous potential of the field of heteroreceptor complexes in the CNS and their receptor-receptor interactions. They offer novel targets for treatment of psychiatry and neurological disorders.|
|Andreas||Kardamakisfirstname.lastname@example.org||Dept. of Neuroscience||Kardamakis||720030834||Preclinical||We are a newly established research team that aims to understand how the brain implements computations that link sensory inputs to motor actions with particular focus on visual-motor processing within the superior colliculus and its interaction with the basal ganglia and neocortex for the control of gaze movements. To achieve this goal, we will take an innovative that combines in vivo electrophysiology, optogenetics and mouse genetics with a virtual-reality system to simulate a visual environment during spatial navigation.|
|email@example.com||NVS||Neurogeriatrics||-||Clinical||depression and cognitive disorders|
|Helena||Karlströmfirstname.lastname@example.org||NVS||Karlström||-||Preclinical||Cell and animal models on inherited form of vascular dementia (CADASIL). Molecular, biochemical work to understand the mechanisms behind the disease. Development of an active and passive vaccination approach as well as diagnostic assay to monitor disease progress and treatment efficacy.|
|Daniel||Ferreiraemail@example.com||NVS||Imaging Group (http://ki.se/en/nvs/imaging-research)||720128047||Clinical||Neuroimaging, cognition and CSF biomarkers in healthy aging and neurodegenerative disorders (http://ki.se/en/people/danife)|
|Robert||Månssonfirstname.lastname@example.org||Laboratory Medicine||Månsson lab||733140128||Preclinical/Clinical||My laboratory focuses on epigenetics in normal B-cell development and chronic lymphocytic leukemia mainly. Our studies of normal B-cell development are mainly focused around understanding gene regulation in the different stages of maturation from stem cells to mature B-cells. The CLL studies on the other hand try to merge CLL genetics and epigenetics to identify relevant mutations that do not directly alter the function of a gene but rather its regulation.
The basis for the CLL project is our interaction with the Hematology Center at Karolinska Sjukhuset and the CLL biobank that we are building up.
|Molly||Stevensemail@example.com||MBB||Molly Stevens' Group||-||Preclinical||The ability to regenerate damaged tissue is one of the great challenges in the fields of tissue engineering and regenerative medicine. Our goal is to study the fundamental science of cell-material interactions and apply this knowledge to the design of biomaterials that translate into clinical solutions|
|Alina||Castellfirstname.lastname@example.org||MTC||Lars-Gunnar Larsson/Alina Castell||08-52486281||Preclinical||Targeting the MYC oncoprotein in childhood cancer
This project is about identifying, characterizing and developing inhibitors targeting the MYC oncoprotein in cancer, in particular childhood cancer. The project includes validation of MYC inhibitors in tumor cell systems using various assays such as cell growth assays, coimmunoprecipitation and protein complementation assays.
|Per||Svenningssonemail@example.com||Klinisk Neurovetenskap||Translationell Neurofarmakologi särsklit Parkinsons sjukdom||070/7498522||Preclinical/Clinical||Parkinson´s disease (PD) is a common neurodegenerative disorders with a largely unknown etiology. The next breakthrough in the treatment of Parkinsons disease (PD) will be aimed at interference or blockade of disease progression, based on insights into the underlying pathogenic process. The development of this new generation of disease-modifying drugs is hampered by the lack of adequate diagnostics and biomarkers that reflects early signs of disease. The motor signs of PD are often preceded by non-motor symptoms including depression, anosmia, REM sleep disorder and constipation.
It is important to develop an improved knowledge of these clinical signs of early PD as neuroprotective and restorative therapies for PD would ideally be offered at an early stage to effectively modify disease progression. The laboratory develops cell and animal models to mimic the progressive disease progression in PD. Biochemical, histological, pharmacological, molecular biological and behavioral techniques are used in these studies.
In clinical studies with patients, clinical ratings, biochemical and imaging (PET and MRI) analyses are being made. A special emphasis is placed on non-motor symptoms of PD and the identification of biomarkers. The information is transferred to a newly developed PD quality register. The research team also studies the pathophysiology of unipolar depression in animal models as well as in patient samples. In addition to PD, other movement disorders including Huntington's disease and ataxia are studied.
|Ola||Hermansonfirstname.lastname@example.org||Department of Neuroscience||Hermanson lab||+46-76-118-7452||Preclinical||Molecular mechanisms of neural development and tumorigenesis|
|email@example.com||Medicine Solna||Clinical Epidemiology Sectionfirstname.lastname@example.org||Clinical||Clinical epidemiological research (registers, clinical cohorts, large datasets) on clinically relevant research questions, such as studies on drug safety, co-morbidities, trreatment outcomes, but also risk factors for disease onset, mainly in chronic inflammayory diseases|
|Sean||Ruddemail@example.com||Science For Life Laboratory, Medical Biochemistry and Biophysics, Karolinska Institutet||Thomas Helleday||Preclinical||Our research is focused upon improving existing treatments for cancer patients. Central to this work is the enzyme SAMHD1, which we identified as a therapeutic barrier to an important group of anti-cancer drugs (Herold & Rudd et al., Nat. Med. 2017; Rudd et al., Mol. Cell. Oncol. 2017). Continuing from this study we wish to further define and, if possible, exploit this role of SAMHD1 by developing small molecule inhibitors of this enzyme. Practically, this project entails working in a small interdisciplinary team using an array of different techniques, including biochemical, biophysical, and cell-based assays.|
|Pontus||Hedberg||Pontus.firstname.lastname@example.org||MTC||Mats Wahlgren||Preclinical/Clinical||Our research is aiming at exploring the role of the histo-blood group ABO system in the pathogenesis of severe Plasmodium falciparum malaria. This is done by in vitro-cultivation of Plasmodium falciparum laboratory strains and patient isolates and assessing their rosetting and cytoadherence (important virulence factors in P. falciparum) characteristics in blood/endothelial cells from patients with different ABO blood groups (BgO, BgA, BgB, BgAB) and subgroups (e.g. A1 vs A2). In the future, the research project will continue to explore this relationship by collecting epidemiological data in malaria-endemic settings.|
|Håkan||Källmenemail@example.com||clinical Neuroscience||Källmen/Gripenberg||073-7218410||Clinical||Evaluation of Housing First, a municipal housing program for homeless, regarding health, substance abuse and recovery.|
|Andrea||Carmine Belinfirstname.lastname@example.org||Neurovetenskap||Carmine Belin||08-52487051||Preclinical||Increase the understanding of the pathophysiology of neurological disorders with a focus on and neurovascular disorders such as cluster headache by identifying, characterizing and modelling genetic markers within the human genome.|
|Sten||Gibsonemail@example.com||Läkelådan||GOped AB||0709660139, 089 212448 eller 50046378||Preclinical/Clinical||Study and manipulation of joint fluid to permit cartilage regeneration|
|Maria||Genanderfirstname.lastname@example.org||CMB||Genander||Preclinical||Its is becoming clear that mechanisms important for developing tissues are often reused in cancers. Cancer stem cells drive tumor formation, analogous to how normal stem cells maintain tissues. We are characterizing transcriptional networks regulating properties of embryonic epidermal stem cells and squamous cell carcinoma cancer stem cells to identify unique and common signatures, with the long term aims of identifying novel therapeutic targets.|
|Tobias||Karlssonemail@example.com||Neuroscience||Lars Olson Lab||Preclinical||We study the regulation of structural plasticity and memory formation using primary hippocampal cell cultures, advanced light microscopy, transgenic mouse models and behavioural testing. Our current topics of investigation include the regulation of structural plasticity by nogo receptor 1, how memory neurons are altered depending on how the memory is learned and how sleep deprivation affects neuronal structure.|
|Carolina||Hagbergfirstname.lastname@example.org||Medicin Huddinge||Integrated Cardio metabolic Centre (ICMC)||070-7572204||Preclinical||Obesity and its associated metabolic diseases are rising at alarming rate worldwide, to great economic cost. Although obesity seems to be regulated mostly in the brain, it is becoming increasingly clear that metabolic disorders stem from dysfunction of the adipose tissue. My research aims to study why adipocytes (fat cells) become dysfunctional during obesity and how we can prevent and reverse this dysfunction in order to counteract metabolic diseases. We do this by studying fat cell metabolism, nutrient uptake and oxygenation using both human and mouse fat cell samples.|
|Klara||Sondénemail@example.com||Institutionen för Medicin, Solna||Färnert||0704565125||Preclinical, Clinical, Public Health||I work within the field of infectious diseases with focus on tropical medicine, malaria and travel medicine.|
|Ana||Amaralfirstname.lastname@example.org||Karolinska Institute - Department of Biosciences and Nutrition (Flemingsberg)||Pekka Katajisto||Preclinical||In our lab we study adult stem cells and we work on the hypothesis that their metabolic state directly determines cell fate upon asymmetric divisions – an essential event in the homeostasis of tissue stem cell niches. This seems to be linked to the type of mitochondria inherited by the cell during those cell divisions. We want to understand how this happens in physiological conditions and then to investigate what changes with ageing. We employ cell culture techniques, metabolic assays, live-imaging (widefield and confocal microscopy) and next-generation sequencing techniques (ATAC-Seq, RNA-Seq). For details see www.katajisto-lab.com.|
|Ninib||Baryawnoemail@example.com||Womens and Childrens Health||Baryawno lab||+46765897740||Preclinical||Basic and translational research in the field of cancer and stem cell biology|
|Axel||Carlsson||Axel.firstname.lastname@example.org||NVS, sektionen för allmänmedicin||Sexual violence and health care||0761745174||Clinical, Public Health||Our aim is to increase the understanding for prevalence, injury development and treatment of sexual abuse injuries. We work with qualitative interviews as well as with register data, we analyze patient journals, conduct treatment studies, we develop and validate theories, etc.|
|Mohammad||Alzrigatemail@example.com||Department of Microbiology, Tumor and Cell Biology||Lars-Gunnar Larsson group||Preclinical||We are studying the function and regulation of the MYC proteins, with the aim of identifying molecules targeting MYC protein activity. One main research theme is to understand how MYC regulates gene expression in cancer by dissecting MYC regulation and interaction with epigenetic machineries and explore the therapeutic potential of combining inhibitors targeting these interactions. One project is focused understading how MYCN-mediated gene silencing contributes to the development of Neuroblastoma, which makes up to 15% of all pediatric cancer deaths. In this project, we will employ state-of-art technologies such as RNA-Seq (gene expression), ChIP-Seq (epigenetic landscape), in situ proximity ligation assay (isPLA - protein-protein interactions), and chemical inhibitors screening to evaluate new drug combinations as novel therapeutic avenue in Neuroblastoma using preclinical disease models. We are looking for motivated students who are interested in cancer research, solving complex research questions, and acquire extensive knowledge in the MYC field, gene expression and epiegentics as well as excellent laboratory experience.|
|Caroline||Ranfirstname.lastname@example.org||Neuroscience||Carmine Belin||Preclinical||Investigating molecular changes in headache disorders using patient specific cell lines. In particular we are interested in the involvement of circadian rhythm in cluster headache and related treatments.|
|ivanka||savic email@example.com||KBH (K6)||Savic||+46709380738||Clinical, Public Health||Behavioral and brain imaging stuidies of gender identity and sexual orientation, effects of sex hormones on the human brain|
|CARL JOHAN||SUNDBERGfirstname.lastname@example.org||Physiology& Pharmacology||Molecular exercise physiology||+46705176886||Preclinical||The aims of our human exercise research are two-fold: 1. To better understand the underlying molecular mechanisms behind the performance and health related adaptations to regular physical activity and 2. To implement and assess physical activity in clinical settings.
To accomplish these aims we conduct 1. Human experimental exercise studies in healthy untrained subjects and highly trained athletes and 2. Physical activity clinical trials in patients with different diagnoses.
The methods we use include: a. exercise capacity testing, b. tissue sampling (skeletal muscle, adipose tissue, blood), c. molecular analyses (transcriptomics, proteomics, metabolomics, epigenomics) with bioinformatics methods, d. immune cell analysis and e. cell studies.
|Terese||Stenforsemail@example.com||LIME||Learning in HealthCareContexts||0737121267||Public Health||We conduct research in Medical Education and evaluation. The methods we use are mainly interviews, surveys and observations|
|David||Zakimfirstname.lastname@example.org||Karolinska Institutet||LIME||-||Clinical, Public Health||Improving and standardizing collection of clinical data from patients with a diversity of clinical problems and the use of non-linear methods for relating complex datasets to clinical diagnoses.|
|Carolina||Hagbergemail@example.com||Medicin Solna||Hagberg research team||070-7572204||Preclinical||Understanding the early disease mechanism in obesity-realted diseases with a focus on the fat or adipose tissue|
|Vicky||Senderfirstname.lastname@example.org||mikrobiologi, tumör- och cellbiologi||Host-pathogen interactions in health and disease||-||Preclinical||We are interested in the co-pathogenesis of respiratory viruses with bacterial pathogens. More specifically, we investigate mechanisms contributing to the increased susceptibility to secondary infection with Streptococcus pneumoniae after influenza virus infection.|
|Olof||Ljungströmemail@example.com||History and Heritage of Medicine / LIME||History of medicine research team, LIME||0706686494||Public Health||The history of the science of medicine, KI history, anatomy|